Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence

Cancer Science

Volumn 94, Issue 10, 2003, Pages 851-857

  Uenishi, Takahiro ^a   Kubo, Shoji ^a   Yamamoto, Takatsugu ^a   Shuto, Taichi ^a   Ogawa, Masao ^a   Tanaka, Hiromu ^a   Tanaka, Shogo ^a   Kaneda, Kenji ^b   Hirohashi, Kazuhiro ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Senior Health Facility Bellflower   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 19; CYTOKERATIN 7; HEPATITIS B CORE ANTIBODY;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER INVASION; CANCER RECURRENCE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PORTAL VEIN; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL RATE; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; KERATINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0242609884     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01366.x     Document Type: Article

References (30)

1. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Cancer 1987; 60: 1400-11.
2. Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Yamazaki O, Kinoshita H. Clinicopathologic factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg 2001; 88: 1-6.
3. Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Konishi M, Kinoshita T, Miyagawa S, Kawasaki S. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000; 127: 498-505.
4. Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE. Liver resection for hilar and peripheral cholangiocarcinoma: a study of 62 cases. Ann Surg 1998; 227: 70-9.
5. Harrison LE, Fong Y, Klimstra DS, Zee SY, Blumgart LH. Surgical treatment of 32 patients with peripheral intrahepatic cholangiocarcinoma. Br J Surg 1998; 85:1068-70.
6. Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol 1995; 26: 956-64.
7. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1992; 31: 11-24.
8. Osborn M, van Lessen G, Weber K, Kloppel G, Altmannsberger M. Different diagnosis of gastrointestinal carcinoma by using monoclonal antibodies specific for individual keratin polypeptides. Lab Invest 1986; 55: 497-504.
9. Lai YS, Thung SN, Gerber MA, Chen ML, Schaffner F. Expression of cytokeratin in normal and diseased livers and in primary liver carcinomas. Arch Pathol Lab Med 1989; 113: 134-8.
10. Balaton AJ, Nehama-Sibony M, Gotheil C, Callard P, Baviera EE. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcino-embryonic antigen and for cytokeratin 19 on paraffin sections. J Pathol 1988; 156: 305-10.
11. Johnson DE, Herndier BG, Medeiros LJ, Warnke RA, Rouse RV. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol 1988; 12: 187-97.
12. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular-cholangiocarcinoma: a histologic and immunohistochemical study. Cancer 1985; 55: 124-35.
13. Leong AS, Sormunen RT, Tsui WM, Liew CT. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined turnouts and metastatic carcinoma. Histopathology 1998; 33: 318-24.
14. Van Eyken P, Sciot R, Paterson A, Callea F, Kew MC, Desmet VJ. Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1988; 19: 562-8.
15. Fischer HP, Altmannsberger M, Weber K, Osborn M. Keratin polypeptides in malignant epithelial liver tumors. Differential diagnostic and histogenetic aspects. Am J Pathol 1987; 127: 530-7.
16. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol 1996; 149: 1167-75.
17. Uenishi T, Kubo S, Hirohashi K, Yamamoto T, Ogawa M, Tanaka H, Shuto T, Kinoshita H. Expression of bile duct-type cytokeratin in hepatocellular carcinoma in patients with hepatitis C virus and prior hepatitis B virus infection. Cancer Lett 2002; 178: 107-12.
18. Couinaud C. Lobes et segments hepatiques. Notes sur larchitecture anatomique et chirrgicale du foie. Press Med 1954; 62: 709-11.
19. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462-503.
20. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 3rd ed. Tokyo: Kanehara Co; 1992. p. 1-76 (in Japanese).
21. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
22. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
23. Kubo S, Kinoshita H, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, Shuto T, Yamamoto T, Ikebe T, Wakasa K. Patterns of and risk factors for recurrence after liver resection for well-differentiated hepatocellular carcinoma: a special reference to multicentric carcinogenesis after operation. Hepatogastroenterology 1999; 46: 3212-5.
24. Sakon M, Umeshita K, Nagano H, Eguchi H, Kishimoto S, Miyamoto A, Ohshima S, Dono K, Nakamori S, Gotoh M, Monden M. Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 2000; 135: 1456-9.
25. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-7.
26. Jwo SC, Chiu JH, Chau GY, Loong CC, Lui WY. Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection. Hepatology 1992; 16: 1367-71.
27. Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, Yamaguchi N, Makuuchi M. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996; 83: 1219-22.
28. Wilkens L, Bredt M, Flemming P, Klempnauer J, Heinrich Kreipe H. Differentiation of multicentric origin from intra-organ metastatic spread of hepatocellular carcinomas by comparative genomic hybridization. J Pathol 2000; 192; 43-51.
29. Ng IO, Guan XY, Poon RT, Fan ST, Lee JM. Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol 2003; 199: 345-53.
30. Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y, Hino O. Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology 1999; 29: 1446-52.